UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 8, 2016
PRONAI THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-37490 | 20-0138994 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 2150 – 885 West Georgia Street Vancouver, British Columbia, Canada |
V6C 3E8 | |
| (Address of principal executive offices) | (Zip Code) |
(604) 558-6536
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 Entry into a Material Definitive Agreement.
On January 8, 2016, ProNAi Therapeutics, Inc. (the “Company”) entered into an office lease (the “Lease”) with Fund VIII 1000 Marina, LLC (the “Landlord”), pursuant to which the Company will lease 4,722 square feet located at 1000 Marina Boulevard, Brisbane, California, 94005, expected to commence on March 1, 2016. The term of the Lease will expire three years and two months after the commencement date, and the Company will have an option to extend the term for one three-year period. The Company’s monthly base rent for the premises will be approximately $15,000 per month for the first year of the Lease, and will be subject to annual increases thereafter of approximately $500 per month during the term of the Lease.
Item 2.03. Creation of a Direct Financial Obligation or an Obligation Under an Off-balance Sheet Arrangement of a Registrant.
The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PRONAI THERAPEUTICS, INC | ||||||
| Date: January 13, 2016 | By: | /s/ Sukhi Jagpal | ||||
| Sukhi Jagpal Chief Financial Officer | ||||||